JFG
SMMT icon

Jefferies Financial Group’s Summit Therapeutics SMMT Stock Holding History

Jefferies Financial Group’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,000
Closed -$1.9M – 2014
2026
Q1 		$1.9M Hold
100,000
– – 0.01% 661
2025
Q4 		$1.75M Buy
100,000
+85,000
+567% +$1.6M 0.01% 868
2025
Q3 		$310K Buy
+15,000
New +$364K ﹤0.01% 1198
2025
Q1 		– Sell
-45,001
Closed -$803K – 1974
2024
Q4 		$803K Buy
+45,001
New +$872K ﹤0.01% 959

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Jefferies Financial Group's SMMT Position: Q2 2026 in Review

Jefferies Financial Group sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 100,000 shares — an estimated $1.9M sold.

Jefferies Financial Group first reported a position in SMMT in Q4 2024 and held it in 4 quarters. The position peaked at $1.9M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Jefferies Financial Group reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 100,000 Summit Therapeutics shares in Q2 2026, an estimated $1.9M.
  • Jefferies Financial Group first reported a position in Summit Therapeutics in Q4 2024 and held it in 4 quarters.
  • Jefferies Financial Group's Summit Therapeutics position peaked at $1.9M in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.